The acquisition will allow Sharp to provide a comprehensive, fully integrated solution for small-to-medium-scale sterile injectable services within the biopharmaceutical sector
Sharp's clinical packaging site in Bethlehem, Pennsylvania. (Credit: GlobeNewswire/Berkshire Sterile Manufacturing)
Sharp, a provider of commercial pharmaceutical packaging and clinical trial supply services, has acquired Berkshire Sterile Manufacturing (BSM), a contract development and manufacturing organisation (CDMO) for an undisclosed sum.
Based in Massachusetts, BSM specialises in fill-finish services for clinical and commercial sterile injectable products.
The acquisition will allow Sharp to provide a comprehensive, fully integrated solution for small-to-medium-scale sterile injectable services within the biopharmaceutical sector.
Sharp’s pre-existing offerings in clinical supply, packaging, and distribution will seamlessly complement BSM’s exceptional sterile manufacturing expertise.
Together, the combined forces of Sharp and BSM are set to offer a comprehensive suite of integrated CDMO services to biopharmaceutical customers on a global scale. This range of services encompasses sterile drug product manufacturing, clinical trial support, commercial packaging, and efficient distribution.
BSM, established in 2014 in Lee, Massachusetts, has maintained a strong commitment to producing clinical and commercial drug products with the utmost emphasis on sterility assurance and quality.
BSM operates an extensive fill finish service, employing specialised isolator-based sterile filling techniques for vials, syringes, and cartridges, along with lyophilization capabilities.
Furthermore, the talented team of 228 employees at BSM will be seamlessly integrated into the Sharp family, continuing their valuable work from their established facility in Lee, Massachusetts.
Sharp president and CEO Kevin Orfan said: “The market continues to demand expertise and capacity in sterile manufacturing due in part to the growth in rare and orphan disease therapies.
“With sterile injectables a huge part of addressing this unmet medical need, the acquisition of BSM allows Sharp to provide a fully integrated solution for our biopharma clients that is a natural extension of our existing injectables and clinical packaging expertise.”
Orfan added: “This acquisition, which builds on the existing partnership between our two companies, will greatly benefit our clients, creating an efficient manufacturing and distribution service for biotech companies developing sterile injectable products across the world.”
Dr Shawn Kinney, one of the co-founders and the CEO of Berkshire Sterile Manufacturing (BSM), will assume a pivotal role within Sharp’s Senior Leadership Team.
In this capacity, he will play a vital role in propelling the growth and advancement of sterile manufacturing services for Sharp’s valued customers.
On a separate note, BSM’s Chief Technology Officer (CTO) and co-founder, Dr Andrea Wagner, has decided to depart from the company.